Hansa Biopharma’s Idefrix leads to one-year GvHD survival in kidney transplant Clinical Trials Arena 20:32 Thu, 28 May
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation PR Newswire (Press Release) 07:30 Wed, 27 May
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR Newswire (Press Release) 03:56 Tue, 26 May
Wedbush Reaffirms Outperform On Hansa Biopharma After ?115M Serb Licensing Deal RTT News 15:45 Wed, 20 May
Hansa Biopharma Enters ?115 Million Licensing Agreement With Serb For Idefirix In Europe And MENA RTT News 11:55 Tue, 19 May
Hansa Biopharma enters into €115 million licensing agreement with Serb Pharmaceuticals for Idefirix in Europe and MENA PR Newswire (Press Release) 07:24 Tue, 19 May
